European Investment Bank

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

Retrieved on: 
Wednesday, January 10, 2024

The disbursement of the second tranche is expected to occur on or about January 18, 2024.

Key Points: 
  • The disbursement of the second tranche is expected to occur on or about January 18, 2024.
  • On January 4, 2024, and in accordance with the Finance Contract, the Company issued 3,144,654 warrants to EIB.
  • After the drawdown of the first tranche in December 20222, the Company was eligible to access the second tranche of €25 million if it met certain conditions precedent described below.
  • Following the achievement of those conditions, the Company decided to draw on the second tranche to reinforce its financial position.

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Retrieved on: 
Thursday, January 4, 2024

The Company will host a webinar on January 9th to expand on the content of the letter and invites you to submit questions both ahead of and during the webinar.

Key Points: 
  • The Company will host a webinar on January 9th to expand on the content of the letter and invites you to submit questions both ahead of and during the webinar.
  • The CEO letter reads as follows:
    Throughout 2023, I communicated my optimism about Scinai's future growth, including our potential to deliver value to our shareholders, stakeholders and partners.
  • Next, Scinai expects to commence toxicology studies which are required to receive regulatory approval to proceed with a first-in-human clinical trial, which Scinai expects to initiate early next year.
  • We expect Scinai Bioservices to grow and generate revenues in support of our NanoAb pipeline development.

Luis de Guindos: Interview with 20 Minutos

Retrieved on: 
Wednesday, January 3, 2024

Communication shocks from the US spill over to risk in the euro area and vice versa, but traditional US shocks show no spillover effects to risk.

Key Points: 
  • Communication shocks from the US spill over to risk in the euro area and vice versa, but traditional US shocks show no spillover effects to risk.
  • Both monetary policy and communication shocks spill over to stocks, with euro area information spillovers being particularly strong.

Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank

Retrieved on: 
Friday, December 22, 2023

20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it has entered into a finance agreement for a loan facility of EUR 90 million from the European Investment Bank ("EIB"), the long-term lending institution of the European Union owned by its Member States.

Key Points: 
  • 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it has entered into a finance agreement for a loan facility of EUR 90 million from the European Investment Bank ("EIB"), the long-term lending institution of the European Union owned by its Member States.
  • "We are very pleased with the endorsement and support from the EIB for our investments in our R&D pipeline," said Henriette Wennicke, Chief Financial Officer of Zealand Pharma.
  • The loan facility may be utilized in up to three tranches of EUR 50 million (Tranche A), EUR 20 million (Tranche B) and EUR 20 million (Tranche C), respectively, with disbursement of each tranche subject to pre-specified milestones being met.
  • The conditions for disbursement of the first tranche (Tranche A) have been met and the EUR 50 million is expected to be available to Zealand in the beginning of 2024.

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

Retrieved on: 
Wednesday, December 20, 2023

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.

Key Points: 
  • The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.
  • Analysis of the baseline characteristics of all patients randomized in the main cohort suggests a patient profile aligned with those of patients randomized in the NATIVE Phase II clinical trial.
  • Lanifibranor continues to show a favorable tolerability profile as confirmed by the third Data Monitoring Committee2 of November 2023.
  • Topline results of the proof-of-concept Phase II clinical trial, LEGEND, evaluating lanifibranor in combination with empagliflozin are expected in the first quarter of 2024.

European Investment Bank to finance Iveco Group N.V. for up to 500 million euros for the decarbonisation of the transport sector

Retrieved on: 
Monday, November 27, 2023

The financing signed represents the first tranche of 450 million euros of the 500 million total approved by the European Investment Bank (EIB) Board of Directors for the operation with Iveco Group.

Key Points: 
  • The financing signed represents the first tranche of 450 million euros of the 500 million total approved by the European Investment Bank (EIB) Board of Directors for the operation with Iveco Group.
  • The EIB financing is aimed at the development of cutting-edge technologies for the electrification, efficiency and safety of the transport sector.
  • The investments will be made by Iveco Group by the end of 2025, mainly in Italy,
    but also in Germany, France, Spain, the Czech Republic and Switzerland.
  • This is the first financial operation between the EIB and Iveco Group.

Inventiva reports 2023 Third Quarter Financial Information¹

Retrieved on: 
Tuesday, November 21, 2023

Net cash used in operating activities amounted to (€69.0) million in the first nine months of 2023, compared to (€40.1) million for the same period in 2022.

Key Points: 
  • Net cash used in operating activities amounted to (€69.0) million in the first nine months of 2023, compared to (€40.1) million for the same period in 2022.
  • R&D expenses for the first nine months of 2023 were up 86 % compared to the same period in 2022.
  • The Company’s revenues for the first nine months of 2023 amounted to €1.9 million, stable from the first six months of 2023, compared to €0.1 million for the same period in 2022.
  • Inventiva has exercised the option to acquire 30% of the shares Hepalys Pharma for the price of 300 yen.

Median Technologies Announces the Drawdown of €8.5m Corresponding to the Final Tranche of the European Investment Bank Loan

Retrieved on: 
Wednesday, December 27, 2023

Median Technologies (Paris:ALMDT) announces that it has received approval from the European Investment Bank to draw down the final tranche of the loan granted on December 18, 2019, and renegotiated at the end of 2022.

Key Points: 
  • Median Technologies (Paris:ALMDT) announces that it has received approval from the European Investment Bank to draw down the final tranche of the loan granted on December 18, 2019, and renegotiated at the end of 2022.
  • The final tranche of €8.5m will be disbursed early January 2024.
  • Median has simultaneously issued 300,000 warrants, at an exercise price of €4.465, with an expiry date in 2035.
    "
  • Tranche B of the EIB's €8.5m financing will enable us to continue our investment plan for eyonis™1 and its early cancer diagnosis programs.

EQS-News: European Investment Bank finances research and development of sustainable technologies at Schaeffler AG

Retrieved on: 
Thursday, December 21, 2023

Funding of research and development expenses for innovative technologies in the automotive and industrial sectors with a focus on renewable energies, electric mobility, and hydrogen

Key Points: 
  • Funding of research and development expenses for innovative technologies in the automotive and industrial sectors with a focus on renewable energies, electric mobility, and hydrogen
    Herzogenaurach, Germany | December 21, 2023 | The European Investment Bank (EIB) has granted Schaeffler AG a loan of 420 million euros.
  • These funds with a term of up to ten years are earmarked for research and development in selected areas, with a focus on sustainable technologies in the European Union.
  • The funding will be used to cover part of the staff costs for research and development of innovative automotive and industrial technologies.
  • The European Investment Bank is also an ideal partner for putting our research and development financing for sustainable technologies on a broad footing.

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

Retrieved on: 
Monday, November 13, 2023

PARIS and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the third quarter of 2023.

Key Points: 
  • “Our robust NBTXR3 clinical program continues to demonstrate potentially transformative efficacy and well-tolerated safety across indications and patient types, including elderly and vulnerable populations.
  • Nanobiotix will host a conference call and live audio webcast on Tuesday, November 14, 2023, at 8:00 am ET / 2:00 pm CET, prior to the open of the U.S. market.
  • During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s operational progress, provide an update on business activities for the third quarter of 2023, and review the latest data presented at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO), before taking questions from participants.
  • A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.